Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors  

作　　者：Federico Pinero Marcelo Silva Massimo Iavarone 

机构地区：[1]Hospital Universitario Austral,Facultad de Ciencias Biomédicas,Universidad Austral,Buenos Aires B1629HJ,Argentina [2]Latin American Liver Research Educational and Awareness Network,Buenos Aires B1629HJ,Argentina [3]Division of Gastroenterology and Hepatology,CRC“A.M.e A.Migliavacca”Center for the Study of Liver Disease,University of Milan,Fondazione IRCCS Ca’Granda Maggiore Hospital,Milan 20121,Italy

出　　处：《World Journal of Gastroenterology》2020年第16期1888-1900,共13页世界胃肠病学杂志（英文版）

摘　　要：During the last decades,further knowledge of hepatocellular carcinoma(HCC)molecular mechanisms has led to development of effective systemic treatments including tyrosine kinase inhibitors(TKIs)and immunotherapy.In this review,we describe first and second line systemic treatment options for advanced HCC.Several trials have evaluated new drugs for the treatment of HCC patients:In first line,lenvatinib resulted non-inferior to sorafenib and it can be used as alternative,even in the lack of evidence for sequential treatment options in second line after lenvatinib.Recently,atezolizumab plus bevacizumab have shown superiority over sorafenib in first-line.Sorafenib-regorafenib sequential administration in selected patients has opened a new paradigm of treatment in advanced HCC with a life expectancy exceeding two years.Other TKIs for second line treatment include cabozantinib and ramucirumab(specifically for patients with Alpha-fetoprotein values≥400 ng/mL).The combination of TKIs with immunotherapy may represent a big step forward for these patients in the near future.

关 键 词：HEPATOCELLULAR CARCINOMA SYSTEMIC OPTIONS SEQUENCING Advanced Future 

分 类 号：R73[医药卫生—肿瘤]